IL6 and metabolic syndrome: Given that tocilizumab is an IL-6 inhibitor which blocks the IL-6 receptor, it was found that IL-6 levels appear to be increased after treatment, which suggests that the mechanism underlying dyslipidemia is due to the direct effect of IL-6 [4].